GADD45β activators constitute a diverse and sophisticated array of chemicals, each playing a unique role in modulating the activation of GADD45β, a critical player in [specific cellular process or pathway]. The intricate regulatory network governing GADD45β activation is orchestrated by these compounds, which act through distinct mechanisms, targeting various signaling pathways and cellular processes. Pifithrin-α stands out as a GADD45β activator by inhibiting p53, a transcription factor known for its role as a repressor of GADD45β. The chemical prevents p53-mediated repression, thereby promoting GADD45β expression and subsequent activation. This emphasizes the importance of understanding the interplay between GADD45β and its regulatory factors for targeted modulation. SB203580, another activator, operates by inhibiting p38 MAPK. GADD45β is positively regulated by p38 MAPK, and the inhibition by SB203580 relieves this positive control, promoting GADD45β activation. The chemical intricately navigates the MAPK pathway, showcasing the specificity required for effective modulation of GADD45β.
Trichostatin A emerges as a GADD45β activator through the inhibition of histone deacetylases (HDACs). GADD45β expression is repressed by HDACs, and trichostatin A-mediated inhibition facilitates GADD45β gene expression, leading to enhanced GADD45β activation. This underscores the role of epigenetic regulation in the control of GADD45β. Camptothecin, a DNA-damaging agent, activates GADD45β by inducing DNA damage, showcasing the responsiveness of GADD45β to genotoxic stress. Sodium butyrate, like trichostatin A, activates GADD45β through HDAC inhibition, providing another avenue for epigenetic modulation of GADD45β. Leflunomide activates GADD45β by inhibiting dihydroorotate dehydrogenase (DHODH), preventing DHODH-mediated activation and promoting GADD45β activity. Sanguinarine activates GADD45β by inhibiting STAT3, relieving STAT3-mediated repression and enhancing GADD45β activation. In summary, the comprehensive understanding of GADD45β activation requires insights into the intricate interplay between specific signaling pathways and cellular processes. The identified GADD45β activators, each with its distinct mode of action, collectively contribute to unraveling the complexity of GADD45β regulation, providing valuable tools for targeted modulation in diverse cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pifithrin-α hydrobromide | 63208-82-2 | sc-45050 sc-45050A | 5 mg 25 mg | $120.00 $300.00 | 36 | |
Pifithrin-α(HBr) activates GADD45β by inhibiting p53. GADD45β is a downstream target of p53, and Pifithrin-α prevents p53-mediated repression, promoting GADD45β expression and subsequent activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A activates GADD45β by inhibiting HDACs. GADD45β expression is repressed by HDACs, and trichostatin A-mediated inhibition promotes GADD45β gene expression and subsequent activation. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2'-deoxycytidine activates GADD45β by inhibiting DNA methylation. GADD45β expression is epigenetically regulated, and demethylation by 5-Aza-2'-deoxycytidine promotes GADD45β activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin activates GADD45β by inhibiting PI3K. GADD45β is negatively regulated by PI3K, so Wortmannin-mediated inhibition relieves this suppression, promoting GADD45β activation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 activates GADD45β by inhibiting the TGF-β receptor. TGF-β negatively regulates GADD45β, so SB431542 prevents TGF-β-mediated repression, promoting GADD45β activation. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin activates GADD45β by inducing DNA damage. GADD45β is a DNA damage-responsive gene, and Camptothecin-induced DNA damage promotes GADD45β expression and subsequent activation. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate activates GADD45β by inhibiting HDACs. Similar to trichostatin A, sodium butyrate promotes GADD45β expression by inhibiting HDACs, leading to enhanced GADD45β activation. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide activates GADD45β by inhibiting DHODH. GADD45β is positively regulated by DHODH, and Leflunomide prevents DHODH-mediated activation, promoting GADD45β activity. | ||||||
Sanguinarium | 2447-54-3 | sc-473396 | 10 mg | $220.00 | ||
Sanguinarine activates GADD45β by inhibiting STAT3. GADD45β is negatively regulated by STAT3, and Sanguinarine-mediated inhibition relieves this suppression, promoting GADD45β activation. | ||||||